BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38274817)

  • 1. Establishment and immune phenotyping of patient-derived glioblastoma models in humanized mice.
    Liu L; van Schaik TA; Chen KS; Rossignoli F; Borges P; Vrbanac V; Wakimoto H; Shah K
    Front Immunol; 2023; 14():1324618. PubMed ID: 38274817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.
    Xia S; Lal B; Tung B; Wang S; Goodwin CR; Laterra J
    Neuro Oncol; 2016 Apr; 18(4):507-17. PubMed ID: 26320116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies.
    Khalsa JK; Shah K
    Cells; 2021 Feb; 10(3):. PubMed ID: 33668856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models.
    Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL
    Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413
    [No Abstract]   [Full Text] [Related]  

  • 5. Translational Orthotopic Models of Glioblastoma Multiforme.
    El Meskini R; Atkinson D; Weaver Ohler Z
    J Vis Exp; 2023 Feb; (192):. PubMed ID: 36876943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumoricidal stem cell therapy enables killing in novel hybrid models of heterogeneous glioblastoma.
    Satterlee AB; Dunn DE; Lo DC; Khagi S; Hingtgen S
    Neuro Oncol; 2019 Dec; 21(12):1552-1564. PubMed ID: 31420675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Microenvironment in Glioblastoma Subtypes.
    Chen Z; Hambardzumyan D
    Front Immunol; 2018; 9():1004. PubMed ID: 29867979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
    Seyfrid M; Maich WT; Shaikh VM; Tatari N; Upreti D; Piyasena D; Subapanditha M; Savage N; McKenna D; Mikolajewicz N; Han H; Chokshi C; Kuhlmann L; Khoo A; Salim SK; Archibong-Bassey B; Gwynne W; Brown K; Murtaza N; Bakhshinyan D; Vora P; Venugopal C; Moffat J; Kislinger T; Singh S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types.
    Khalsa JK; Cheng N; Keegan J; Chaudry A; Driver J; Bi WL; Lederer J; Shah K
    Nat Commun; 2020 Aug; 11(1):3912. PubMed ID: 32764562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence.
    Oudin A; Moreno-Sanchez PM; Baus V; Niclou SP; Golebiewska A
    BMC Cancer; 2024 Jan; 24(1):3. PubMed ID: 38166949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.
    Wakimoto H; Mohapatra G; Kanai R; Curry WT; Yip S; Nitta M; Patel AP; Barnard ZR; Stemmer-Rachamimov AO; Louis DN; Martuza RL; Rabkin SD
    Neuro Oncol; 2012 Feb; 14(2):132-44. PubMed ID: 22067563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
    Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
    Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments.
    Shen Y; Grisdale CJ; Islam SA; Bose P; Lever J; Zhao EY; Grinshtein N; Ma Y; Mungall AJ; Moore RA; Lun X; Senger DL; Robbins SM; Wang AY; MacIsaac JL; Kobor MS; Luchman HA; Weiss S; Chan JA; Blough MD; Kaplan DR; Cairncross JG; Marra MA; Jones SJM
    Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19098-19108. PubMed ID: 31471491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors.
    Ahmed N; Salsman VS; Kew Y; Shaffer D; Powell S; Zhang YJ; Grossman RG; Heslop HE; Gottschalk S
    Clin Cancer Res; 2010 Jan; 16(2):474-85. PubMed ID: 20068073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid Cells in Glioblastoma Microenvironment.
    De Leo A; Ugolini A; Veglia F
    Cells; 2020 Dec; 10(1):. PubMed ID: 33374253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.
    Candolfi M; Curtin JF; Nichols WS; Muhammad AG; King GD; Pluhar GE; McNiel EA; Ohlfest JR; Freese AB; Moore PF; Lerner J; Lowenstein PR; Castro MG
    J Neurooncol; 2007 Nov; 85(2):133-48. PubMed ID: 17874037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy.
    Chen C; Jing W; Chen Y; Wang G; Abdalla M; Gao L; Han M; Shi C; Li A; Sun P; Jiang X; Yang Z; Zhang S; Zhang J; Tang C; Liu Y; Zhang R; Xu F; Dong B; Li X; Liu M; Qiang B; Sun Y; Wei X; Li J; Hu Q; Jiang X
    Sci Transl Med; 2022 Aug; 14(656):eabn1128. PubMed ID: 35921473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Cell Atlas Reveals Complexity of the Immunosuppressive Microenvironment of Initial and Recurrent Glioblastoma.
    Fu W; Wang W; Li H; Jiao Y; Huo R; Yan Z; Wang J; Wang S; Wang J; Chen D; Cao Y; Zhao J
    Front Immunol; 2020; 11():835. PubMed ID: 32457755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade.
    Chen Z; Herting CJ; Ross JL; Gabanic B; Puigdelloses Vallcorba M; Szulzewsky F; Wojciechowicz ML; Cimino PJ; Ezhilarasan R; Sulman EP; Ying M; Ma'ayan A; Read RD; Hambardzumyan D
    Glia; 2020 Oct; 68(10):2148-2166. PubMed ID: 32639068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
    Stechishin OD; Luchman HA; Ruan Y; Blough MD; Nguyen SA; Kelly JJ; Cairncross JG; Weiss S
    Neuro Oncol; 2013 Feb; 15(2):198-207. PubMed ID: 23262510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.